Dallas-based spectral imaging device developer Spectral AI received a $1 million investment to support its recently formed subsidiary, Spectral IP.
The company’s lead product, the DeepView wound imaging system, uses multispectral imaging and AI to provide an immediate wound healing prediction to clinicians with information that is not visible to the human eye.
With the investment, Spectral IP will focus on advancing intellectual property in the broader AI ecosystem through acquisitions, strategic partnerships, and collaborations with AI technology providers, healthcare institutions, and research organizations, the company said.
